A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

Enrolling by invitation

Conditions studied: Growth Hormone Deficiency, Neoplasms, Diabetes Mellitus Type 2

In brief

The aim of this study is to look at the long-term safety and clinical parameters of somapacitan in paediatric participants with growth hormone deficiency under routine clinical practice conditions. The study population will include 400 paediatric growth hormone deficient participants from the Global Registry for Novel Therapies in Rare Bone and Endocrine Conditions (GloBE-Reg) treated with once-weekly somapacitan and fulfilling the eligibility criteria of the study. The total duration of the study is planned to 10 years consisting of a 5-year recruitment period in the GLoBE-Reg followed by a 5-year follow-up period.

Key facts

Study ID

NCT06709040

Run by

Novo Nordisk A/S

People needed

500

Starts

2024-12-13

Expected to finish

2034-04-14

Last updated by the study team

2026-04-06

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Treated with commercially available somapacitan according to local practice at the discretion of the physician.
• Primary confirmed diagnosis of growth hormone deficiency as per local practice.
• Male or female below 18 years of age at the time of signing informed consent in the GLoBE-Reg.

You may not qualify if…

• Participants with active malignancy or in treatment for active pre-existing malignancy.

Where it is running

• University of Glasgow — Glasgow, Scotland, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.